ARCHIVES

Autologous BMT Equivalent To Allogeneic For Myeloma

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

ODAC Recommendation for Pertuzumab Signals FDA’s Resolve In Granting Accelerated Approvals

September 20, 2013

NIH Panel Calls For More Attention to Cancer Pain

July 26, 2002

Screening Guidelines Differ Among Major Medical Organizations

January 16, 1998

Eight Firms Join AACR As Sustaining Members

April 25, 1997

In Brief: NIH Call For Review Group Nominations Brings 8,000 Names For 400 Vacancies

August 17, 1979

Drug pricing: Amgen’s “bundling” violates antitrust laws, J&J claims in suit.

October 14, 2005